Delcath (DCTH) Q2 Revenue Jumps 210%

Delcath Systems (NASDAQ:DCTH), a medical device and pharmaceutical company known for liver-directed cancer therapies, announced its earnings for the second quarter of fiscal 2025 on August 6, 2025. The company reported a sharp increase in revenue, reaching $24.2 million (GAAP).—exceeding analyst GAAP estimates of $22.94 million. Gross margin (GAAP) improved to 86%, and Non-GAAP adjusted EBITDA was $9.8 million, turning positive versus a loss a year ago. Diluted EPS (GAAP) was $0.07, beating the expected $0.03. Delcath’s quarter saw stronger-than-expected adoption of its HEPZATO KIT in the U.S, continued U.S. center expansion, and progress in clinical development for new cancer indications. The results positioned the company above expectations. Source: Analyst estimates for the quarter provided by FactSet. Delcath Systems is focused on developing and commercializing therapies that deliver high doses of chemotherapy directly to the liver. Its core product, the HEPZATO KIT, is a combination drug and device system for treating uveal melanoma with unresectable liver metastases. HEPZATO KIT received approval from the U.S. Food and Drug Administration (FDA) in August 2023, with its first commercial patients treated in January 2024.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool